Dr Matthew Russell Warden, OD in Algood, TN - Medicare Optometry Provider

Dr Matthew Russell Warden, OD is a medicare enrolled "Optometrist" provider in Algood, Tennessee. He went to Southern College Of Optometry and graduated in 2006 and has 18 years of diverse experience with area of expertise as Optometry. His current practice location is 589 W Main St, Algood, Tennessee. You can reach out to his office (for appointments etc.) via phone at (931) 537-3937.

Dr Matthew Russell Warden is licensed to practice in Tennessee (license number 2677) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1689608507.

Contact Information

	Dr Matthew Russell Warden, OD
	589 W Main St, Algood, TN 38506-5320
	(931) 537-3937
	Not Available

Healthcare Provider's Profile

Full Name	Dr Matthew Russell Warden
Gender	Male
Speciality	Optometry
Experience	18 Years
Location	589 W Main St, Algood, Tennessee
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Matthew Russell Warden attended and graduated from Southern College Of Optometry in 2006

NPI Data:

NPI Number: 1689608507
Provider Enumeration Date: 07/10/2006
Last Update Date: 07/08/2007

Medicare PECOS Information:

PECOS PAC ID: 3476653064
Enrollment ID: I20070711000839

Medical Identifiers

Medical identifiers for Dr Matthew Russell Warden such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1689608507	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	2677 (Tennessee)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Matthew Russell Warden is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Matthew Russell Warden, OD 519 Mason Rd, Cookeville, TN 38501-7928 Ph: (931) 372-7535	Dr Matthew Russell Warden, OD 589 W Main St, Algood, TN 38506-5320 Ph: (931) 537-3937

News Archive

Cytochalasin B-induced membrane vesicles successfully tested as vector for anti-tumor drug delivery

Extracellular vesicles (EV) represent a promising vector system for biomolecules and drug delivery due to their natural origin and participation in intercellular communication.

Landmark Legal Foundation to sue the President if 'Slaughter Rule' is used to enact H.R. 3590

Mark R. Levin, president of Landmark Legal Foundation, today issued a warning to the leadership of the U.S. House of Representatives about the possible use of the so-called "deem and pass," "self-executing," or "Slaughter Rule" to enact H.R. 3590, the legislative version of President Obama's healthcare proposal that has been previously approved by the Senate.

Medidata Solutions announces multi-year contract extension with Shire

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced a multi-year contract extension with Shire plc for use of Medidata Grants Manager™ and CRO Contractor™ benchmarking and analysis tools for investigator site and contract research organization (CRO) trial budget planning and forecasting.

American College of Chest Physicians releases new clinical guidelines on EBUS-guided TBNA

The American College of Chest Physicians announced the release of new clinical guidelines on endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA). The guideline, which applies to a common bronchoscopic test, contains 12 recommendations including best practices related to patient factors and procedural aspects.

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

Dr Matthew Russell Warden, OD - Medicare Optometrist in Algood, TN